Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06530927

Microclots and Neutrophil Activation as Potential Indicators for Stroke Risk and Reperfusion Failure

Stroke remains a major health burden worldwide. Many patients are severely disabled and stay in need of care. Mechanical thrombectomy has dramatically improved outcomes for stroke patients with large vessel occlusions, yet 40-50% of patients with successful recanalization remain severely disabled despite successful recanalization, a scenario called "futile recanalization". One of the causes for this lack of treatment effect is capillary obstruction, or "no reflow", potentially resulting from activated neutrophils and micrometer-sized blood clots. To address this issue, we employ digital holotomographic and atomic force microscopy to investigate the structural and chemical characteristics of blood and clot material in stroke patients and individuals at high risk of developing a stroke. Our study elucidates the association of activated neutrophils and microclots with stroke risk, and may be associated with clinical outcome, stroke ethology and reperfusion failure in patients with stroke. Leveraging label-free microscopy tools, could potentially lead to the discovery of new biomarkers for individualized stroke treatment and prevention, ultimately offering rapid identification of at risk patients and improving clinical outcomes

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Background:

Stroke remains a major health burden worldwide. Many patients are severely disabled and stay in need of care. Since introducing mechanical thrombectomy as a therapeutic option, clinical outcome has drastically improved over the last few years. However, despite successful macrovascular reperfusion (recanalization), patients with stroke still have a significant risk (about 40-50%) of remaining severely disabled, a scenario called "futile recanalization". One of the causes for this lack of treatment effect is capillary obstruction, or "no reflow", potentially resulting from activated neutrophils and micrometer-sized blood clots. Previous work in rodent stroke models demonstrated that removal of these capillary stalls indeed improves reperfusion and recovery after stroke. However, there is a lack of knowledge regarding the role of neutrophils or microclots in patients with stroke, and their potential to indicate reperfusion failure.

Aim:

The goal of our study is to search for activated neutrophils and microclots in peripheral blood samples from patients with stroke. We anticipate that neutrophil and microclot characteristics such as size, shape, or surface structure may indicate stroke risk, and may be associated with clinical outcome, stroke ethology and reperfusion failure in patients with stroke. Our goal is to improve the prediction of stroke risk and treatment success.

Methodology:

We plan to prospectively include 500 patients with acute and chronic stroke, as well as a control group. We have teamed up with biophysicists from the Swiss Federal Laboratories for Materials Science (EMPA) using the novel microscopic tools 3D rotational digital tomography (DHTM) to achieve an unprecedented resolution of less than 10 μm for detection of altered neutrophil phenotypes and microclots in peripheral blood samples. Furthermore, in patients undergoing mechanical thrombectomy, retrieved clots will be analyzed with high-density micro-computertomography (micro-CT). Quantity, mechanical and structural properties of microclots and neutrophils will be correlated with risk of reperfusion failure, stroke recurrence and clinical recovery. Analyses of clots from patients with large vessel occlusion will be used to derive risk of reperfusion failure along with most likely source of the clot, and thus, most likely stroke etiology.

Potential Significance:

Current diagnostic tools are insufficient to predict response to treatment, clot source or stroke recurrence risk. Our project has the potential to discover new, clinically applicable biomarkers identifying patients at risk within a few hours, enabling individualized stroke treatment and prevention.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients without acute stroke CS or CSG

  • No previous stroke or previous stroke ≥ 1 year ago
  • Signed informed consent

Patients with acute stroke (AS-noTx, AS-IVT, AS-MT):

  • Patients admitted with high suspicion of acute ischemic stroke
  • Time of onset of stroke symptoms ≤ 12 hours
  • Consent according to the regulations of research in an emergency situation
  • Ischemic stroke later confirmed

Exclusion criteria

All groups:

  • Pregnancy
  • Age under 18 years

Acute Stroke no Therapy

  • Acute treatment with IVT or with MT

Acute Stroke IVT-Group • Acute treatment with MT or without IVT

Acute Stroke MT-Group

  • Acute treatment without MT

Treatment and study plan

3D rotational digital tomography

Diagnostic Test

DHTM is label-free and records the phase shift of low-energy light passing through the specimen on a transparent surface with minimal perturbation. DHTM measures the refractive index (RI) and computes the refractive index gradient (RIG), unveiling optical heterogeneity in cells. We will analyze blood samples for the detection of altered neutrophil phenotypes and microclots.

Atomic Force Microscopy

Diagnostic Test

The atomic force microscope (AFM) is widely used in materials science and has found many applications in biological sciences but has been limited in use in vision science. The AFM can be used to image the topography of soft biological materials in their native environments. We will analyze blood samples for the detection of altered neutrophil phenotypes and microclots

Micro-Computertomography

Diagnostic Test

Micro-CT is a 3D imaging technique utilizing X-rays to see inside an object, slice by slice. Micro-CT, also called microtomography or micro computed tomography, is similar to hospital CT or "CAT" scan imaging but on a small scale with greatly increased resolution. Samples can be imaged with pixel sizes as small as 100 nanometers and objects can be scanned as large as 200 millimeters in diameter. We will use micro-CT to analyze blood clots from patients with large vessel occlusion.

Primary outcomes

  1. Quantification and characterization of microclots

    Time frame: First Visit/Admission and patients with acute stroke after 24 hours, 3 months and 1 year

    3D rotational digital tomography and atomic force microscopy

    imaging outcome measurements:

    • size: length (µm), width (µm)
    • dry mass (g/dl)
    • praevalence (count in numbers)
    • composition (platelet aggregate vs. fibrin-rich microclots vs. microclot composite)
  2. Quantification and characterization of neutrophils

    Time frame: First Visit/Admission and patients with acute stroke after 24 hours, 3 months and 1 year

    3D rotational digital tomography and atomic force microscopy

    image morphological outcome measurements:

    • size: diameter (µm), surface area (µm2), volume (fl), thickness (µm), sphericity
    • dry mass (g/dl)
    • praevalence (count in numbers)
    • activation state (activated vs. not activated vs. dead)
  3. Evaluation of reperfusion failure in patients with large vessel occlusion and mechanical thrombectomy

    Time frame: <24 hours in patients with mechanical thrombectomy

    Defined by successfull macrovascular reperfusion (TICI >=2c) and insufficient microvascular reperfusion with the outcome measurment (yes/no)

    Successfull macrovasular reperfusion is defined according to the mTICI score 2c or 3.

    Microvascular reperfusion success will be evaluated with thresholds were used to discriminate between microvascular hypoperfusion and reperfusion, calculated from perfusion images obtained on computed tomography (CTP) or magnetic resonance perfusion imaging (MRP).

Secondary outcomes

  1. Change in National Institute of Health Score Scale (NIHSS)

    Time frame: First Visit/Admission and patients with acute stroke after 24 hours, 3 months and 1 year

    will be assessed using National Institutes of Health Stroke Scale (NIHSS)

    NIHSS

    13 assessed functional domains Range 0-42, higher score indicates severe impairment

  2. Degree of disability or dependence assessed by the modified ranking scale (mRS)

    Time frame: First Visit/Admission and patients with acute stroke after 24 hours, 3 months and 1 year

    will be assessed using modified Rankin Scale (mRS)

    mRS

    Range: (0-6) 0 = no symptoms, 6 = death, higher score indicates severe impairment

  3. Assessment Quality of Life using European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L)

    Time frame: 365 days

    EQ-5D-5L

    Evaluation of 5 different aspects of health with likert scale (1-5)

    MOBILITY SELF-CARE USUAL ACTIVITIES PAIN / DISCOMFORT ANXIETY / DEPRESSION Each domain is scored individually, higher values indicate higher impairment of quality of life

  4. Incidence of new cardiovascular disease

    Time frame: 365 days

    Stroke, heart attack, brain bleeding

  5. All-cause mortality

    Time frame: 365 days

    Mortality

Study contacts

Contact information is provided by the study sponsor or research team.

Lukas Otto, Dr. med.

CONTACT

[email protected]

+41 43 253 13 01

Susanne Wegener, Prof.

CONTACT

[email protected]

+41 44 255 10 78

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Collaborators

  • Empa, Swiss Federal Laboratories for Materials Science and Technology

Registry information

Official study title

Micro-clots and Neutrophil Activation as Potential Indicators for Stroke Risk and Reperfusion Failure The CLOTSAFE - Study (Micro-CLOTs, Stroke Risk, Activated Neutrophils, Reperfusion FailurE)

Acronym: CLOTSAFE

Important dates

Study start
2025
Primary completion
2030
Study completion
2030
First posted
Jul 31, 2024
Registry last updated
Aug 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.